ResearcherEmory UniversityActive in the last 2 years

Cecilia Grace Ethun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-0694-7951; OpenAlex author ID A5041030324. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gilbert Zvikomborero Murimwa · 1 shared paper, 2025 · strength 0.20
- Paper SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. DOI 10.1158/0008-5472.can-24-1970 ↗
Huocong Huang · 1 shared paper, 2025 · strength 0.20
- Paper SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. DOI 10.1158/0008-5472.can-24-1970 ↗
Jason B. Fleming · 1 shared paper, 2025 · strength 0.20
- Paper SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. DOI 10.1158/0008-5472.can-24-1970 ↗
Aatur Dilip Singhi · 1 shared paper, 2025 · strength 0.20
- Paper SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. DOI 10.1158/0008-5472.can-24-1970 ↗
Rolf A. Brekken · 1 shared paper, 2025 · strength 0.20
- Paper SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. DOI 10.1158/0008-5472.can-24-1970 ↗
David A. Kooby · 2 shared papers, 2016 · strength 0.18
- Paper The importance of surgical margins in pancreatic cancer. DOI 10.1002/jso.24092 ↗
- Paper Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Pha… DOI 10.1002/jso.24317 ↗
Volkan N. Adsay · 1 shared paper, 2016 · strength 0.06
- Paper Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Pha… DOI 10.1002/jso.24317 ↗
Juan Manuel Sarmiento · 1 shared paper, 2016 · strength 0.06
- Paper Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Pha… DOI 10.1002/jso.24317 ↗
Lauren McLendon Postlewait · 1 shared paper, 2016 · strength 0.06
- Paper Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Pha… DOI 10.1002/jso.24317 ↗
Shishir Kumar Maithel · 1 shared paper, 2016 · strength 0.06
- Paper Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Pha… DOI 10.1002/jso.24317 ↗
Bassel F. El‐Rayes · 1 shared paper, 2016 · strength 0.06
- Paper Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Pha… DOI 10.1002/jso.24317 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.